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Botulinum neurotoxin type-A (BoNT-A) has been used in association with other
interventions in the management of spasticity in children with cerebral palsy (CP) for
almost two decades. This consensus statement is based on an extensive review of the
literature by an invited international committee. The use of BoNT-A in the lower
limbs of children with spasticity caused by CP is reported using the American
Academy of Neurology Classiﬁcation of Evidence for therapeutic intervention. Ran-
domized clinical trials have been grouped into ﬁve areas of management, and the
outcomes are presented as treatment recommendations. The assessment of children
with CP and evaluation of outcomes following injection of BoNT-A are complex, and
therefore, a range of measures and the involvement of a multidisciplinary team is
recommended. The committee concludes that injection of BoNT-A in children with
CP is generally safe although systemic adverse events may occur, especially in children
with more physical limitations (GMFCS V). The recommended dose levels are
intermediate between previous consensus statements. The committee further concludes
that injection of BoNT-A is eﬀective in the management of lower limb spasticity in
children with CP, and when combined with physiotherapy and the use of orthoses,
these interventions may improve gait and goal attainment.
Introduction & objectives
Botulinum neurotoxin type-A (BoNT-A) has been used
in the management of spasticity in the lower limbs of
children with CP for more than 15 years, with the ﬁrst
reports by Koman et al. from the United States in 1993
[1] and Graham et al. in the United Kingdom in 1994
[2]. The original indication, which remains the most
common today, was injection of the gastrocsoleus for
the correction of spastic equinus or improvement of
equinus gait (toe-walking). Since the ﬁrst reports,
indications have been extended to almost every major
muscle in the lower limb, with varying degrees of suc-
cess and variable levels of evidence.
This international consensus statement reviews the
evidence for the use of BoNT-A therapy in the lower
limbs of children with spasticity caused by CP, formu-
lates them into appropriate treatment recommendations
and identiﬁes areas for future research based on gaps in
the literature. In addition, areas of clinical relevance
without high levels of evidence have been reviewed
including assessments, outcome measures, adjunctive
therapies, recommended doses, dilution, muscle locali-
zation techniques and screening for adverse events. A
suggested management algorithm is also provided.
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Literature was searched and appraised using a con-
ventional evidence hierarchy. The highest levels of evi-
dence available were used to develop recommendations,
with randomized controlled trials (RCTs) and system-
atic reviews preferentially sought. Only when RCT or
systematic review evidence was not available, were
lower level evidence and practice-based evidence
included to answer clinical questions raised at the
International BoNT Consensus Workshop. Expert
opinion where included has been clearly labelled and
should be interpreted with judicious caution. Recom-
mendations for research were made based on the gaps
identiﬁed in the literature. All recommendations were
graded based on the American Academy of Neurology
evidence classiﬁcation [3].
Definition and classification of cerebral palsy
CP is the most common cause of physical disability of
childhood in the developed world, with an incidence
of 2–2.5 per 1000 live births [4]. The heterogeneity
of clinical phenotypes is one of the most striking fea-
tures in CP. Impairment of gross motor function and
abnormalities of tone are deﬁning features of CP [5].
Spasticity aﬀects between 70 and 80 per cent of children
with CP [6]; however, precise diagnosis of the move-
ment disorder can be diﬃcult as spasticity often
co-exists with dystonia. Management of spasticity will
be the focus in this review because it is the most com-
mon movement disorder in cerebral palsy. The treat-
ment of dystonia is beyond the scope of this review.
The Upper Motor Neurone syndrome
CP is the most common cause of UMN syndrome in
children. Spasticity, deﬁned as a velocity-dependent
increase in tonic stretch reﬂexes [5], is but one mani-
festation of the Upper Motor Neurone (UMN) Syn-
drome.
The UMN syndrome presents both positive and
negative features [4]. The positive features include
spasticity, co-contraction and hyper-reﬂexia. The neg-
ative features include weakness, impaired selective
motor control, balance deﬁcits and fatigability of
skeletal muscle. There has been a tendency for health
professionals to concentrate on the positive features of
the UMN syndrome because they are clinically obvious
and amenable to modulation. However, the negative
features may be more important to long-term loco-
motor prognosis [7]. In younger children, spasticity is
very prominent, resulting in toe-walking and equinus
gait patterns [7]. In older children and adolescents,
weakness of antigravity muscles frequently results in
various types of ﬂexed knee gait including crouch gait
[8,9].
CP may be classiﬁed by aetiology (when known),
brain imaging, type and topographical distribution of
movement disorder and gross motor function. In re-
cent years, the Gross Motor Function Classiﬁcation
System (GMFCS) [10] has been adopted as the com-
mon language for health professionals to communicate
about gross motor ability in children with CP. The
GMFCS is a ﬁve-level ordinal grading system, which
describes gross motor function with diﬀerent descrip-
tors used for children of diﬀerent ages. The Gross
Motor Function Classiﬁcation System (GMFCS) is
valid, reliable, relatively stable with time and clinically
relevant. It is a classiﬁcation system and not an out-
come measure but is relevant in all discussions in re-
spect of management of CP, because management
goals and selection of relevant interventions must be
based on a sound knowledge of long-term gross motor
prognosis. For example, children at GMFCS levels I
and II walk independently in the community. They
often have relatively mild gait disorders amenable to
management with BoNT-A combined with therapy
interventions. Children at level III need extensive
assistive devices but still manage to ambulate for
shorter distances. Children at GMFCS level IV have
very limited standing and walking ability, and children
at GMFCS level V are non-ambulant. The Children
with GMFCS V may have severe generalized hyper-
tonia, of which spasticity may be only one component,
and may beneﬁt from interventions more global than
BoNT-A. BoNT-A may be indicated for focal tone
management in these children, and when used in this
way, indications are more diﬃcult to deﬁne and out-
comes are less predictable.
Methods: inclusion and exclusion criteria
A literature search completed in April 2008, using the
following search terms:
1 cerebral palsy and
2 spasticity and
3 botulinum neurotoxin or BOTOX or BoNT-A or
BTA or Dysport.
The search revealed a very large number of studies of
varying quality. Only randomized clinical trials (RCTs)
that met the inclusion criteria (Table 1) were retained
and included. Each full article was then reviewed and
classiﬁed by two committee members using the
American Academy of Neurology (AAN) Classiﬁcation
of Evidence for therapeutic intervention and classiﬁca-
tion of recommendations [3]. Where classiﬁcations were
not congruent, a third reviewers opinion and commit-
tee consensus was sought. It was recognized that much
useful information exists in studies and reviews other
than RCTs, especially in relation to methods of
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assessment, outcome measures and adjunctive inter-
ventions. Therefore, these other studies have been
reviewed and information reported as expert opinion.
What is the best way to assess children with
CP for BoNT-A therapy?
Selection for, and/or targeting of, BoNT-A injection in
the lower limb is dependent upon many factors, in
particular, the speciﬁc goals of intervention. Because of
the heterogeneity of children with CP, the aim of
treatment using BoNT-A will vary signiﬁcantly between
individuals. It is important to separate assessment into
(i) patient selection/screening of children for BoNT-A
therapy and (ii) specialist assessments to identify out-
comes of BoNT-A therapy. The tools used are not
necessarily mutually exclusive.
Baseline assessment: screening and selection for
BoNT-A therapy
BoNT-A therapy targets reduction of muscle over-
activity, predominantly spasticity and/or dystonia.
Therefore, it is essential to quantify the presence of
these motor disorders, to diﬀerentiate the spasticity
from the other components of hypertonia and to select
some sensitive measure of change to determine local
responsiveness to BoNT-A. These assessments measure
change at the impairment or body structures and
functions level [11]. This is the level at which BoNT-A
may have a direct impact, with anticipated changes in
gross motor function, goal attainment activities and
participation being indirect and less predictable.
The GMFCS is clearly prognostic of long-term gross
motor ability in CP and helps the family and multi-
disciplinary team identify clinically relevant, realistic
goals. Clinically relevant goals can be broadly grouped
and may include improving gait and function (GMFCS
I–III), improving posture (GMFCS III–V), relieving
pain and discomfort and/or reducing the burden of
care (GMFCS V). As part of the initial assessment, the
clinician should discuss with the family whether the
types of goals they have identiﬁed can be met by
BoNT-A therapy and, if not, what other options may
be available.
Outcome assessment
The authors deﬁne high-quality outcome assessments as
being consistent and free from error (reliable) and
measuring what is intended to be measured (valid). The
tool(s) also need to be responsive to change (able to
detect minimal clinically important diﬀerences) as well
as being tailored to the children involved and the pur-
pose of measurement [12].
No single tool covers all domains of the International
Classiﬁcation of Function and Disability (ICF) [11]. To
assess children with CP comprehensively, a range of
tools are required, some of which are better suited to
clinical use and others for research purposes. It is
recommended that selection of outcome measures
should include at least one measure of body function
and structure (as this relates to local, technical response
of injected BoNT-A) and at least one measure of
function, activity or participation [as related to the
goal(s) of, and satisfaction with, treatment]. Numerous
outcome measures are available for use in children with
CP, yet remarkably, a few published studies utilize an
appropriate range of outcome measures.
Recommendation 1
The multidisciplinary team (MDT) providing the BoNT-A therapy
should choose assessment tools that:
• Reliably differentiate the spasticity from ﬁxed musculoskeletal
contractures and other causes of hypertonia*
• Document the GMFCS and baseline function including, but not
limited to, functional gross motor assessment; care needs; what
the infant/child can/cannot do; analysis of movement; gait
analysis; functional task analysis; and seating/sleeping positions*
• In ambulant children, describe gait and function using scales such
as the Physician Rating Scale (PRS) or Observational Gait Scale
(OGS) ± video recording*
• In non-ambulant children, describe abnormal postures and care
needs in clinically relevant terms using valid and reliable tools*
*Expert opinion.
Tools for the assessment of spasticity in children
with cerebral palsy: clinical versus research
A number of clinical tools have been described for the
assessment of spasticity, dystonia and contracture in
children with cerebral palsy. These scales include the
Tardieu Scale,ModiﬁedTardieu Scale (MTS),Ashworth
Scale, Modiﬁed Ashworth Scale (MAS) and Australian
Spasticity Assessment Scale (ASAS). These tools have
been described, tested andwidely reported. Their beneﬁts
and limitations are widely recognized. However, there
are a number of methods for instrumented measurement
of spasticity, both directly and indirectly, including var-
Table 1 Inclusion criteria
Inclusion criteria
Participants with spasticity caused by CP
Age £ 18 years
Use of BoNT-A (BOTOX & Dysport)
Randomized Controlled Trials
English language
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ious powered systems, resonant frequency and indirectly
using gait analysis. Unfortunately, none of the instru-
mented measures fulﬁl the requirements for a useful tool
in the clinical setting (Table 2). Both the clinical and in-
strumented measures have recently been reviewed by
Johnson and Pandyan [13].
Measurements of body structure and function
Many clinical tools have been described for the
assessment of spastic hypertonia in the literature [14–
26], and a detailed discussion is beyond the scope of this
document.
The Tardieu Scale and the Modiﬁed Tardieu Scale
(MTS)
Despite the Tardieu Scale [26,27] being the most rele-
vant uninstrumented clinical tool for the assessment of
spasticity and being consistent with current deﬁnitions
(in that it examines muscle response and resistance to
passive movement at varying velocities, including rapid
passive movement), it has been found by clinicians to
have limited clinical utility in the paediatric setting as it
is a lengthy procedure. The Modiﬁed Tardieu Scale
(MTS) is a valid, reliable and sensitive abridged version
[18,28–30]. It utilizes the most clinically useful parts of
the Tardieu Scale: the angle of catch at the most rapid
velocity (R1). R1 of the MTS can then be compared
with R2, (joint angle when the muscle length is at its
maximum, assessed by moving the limb through its
entire range of movement (ROM) using slow passive
movement) [31]. The relationship between the R1 and
R2 estimates the relative contributions of spasticity
compared to contracture [18]. Additional recommen-
dations [32] include that R2 needs to be tested imme-
diately preceding the R1, and the R1 needs to be tested
three times in rapid succession. This procedure ensures
identiﬁcation of voluntary eﬀort [32] and overcomes the
inertia of the sliding muscle ﬁbres [33,34], allowing
the neural component to be isolated. It also ensures that
the condition of the muscle prior to testing R1 can be
replicated [32,35].
Modiﬁed Ashworth Scale (MAS)
The most commonly reported measure of spasticity in
the literature is the Modiﬁed Ashworth Scale (MAS)
[15]. As the MAS is performed at a single velocity, it is
not truly able to distinguish, describe, measure or rate
spasticity. Rather, the MAS measures passive resistance
to motion that may or may not be caused by an
increased response to stretch. Despite its widespread
use and its ability to identify general hypertonia, it is
recommended that this tool no longer be used to
describe spasticity because of its limited validity.
Australian Spasticity Assessment Scale (ASAS)
The Australian Spasticity Assessment Scale (ASAS)
addresses the limitations of the MAS. The ASAS scores
the muscles response to slow and rapid passive move-
ment on a 5-point ordinal scale without the subjectivity
and wording ambiguities of the MAS. This tool pro-
vides clinicians with a user-friendly, quick to adminis-
ter, valid and reliable alternative to other spasticity
measures. Early research suggests this tool has excellent
reliability and clinical utility and therefore oﬀers a new,
alternative spasticity assessment tool [36].
A clear proﬁle of the spasticity is presented by the
MTS and the ASAS together (Table 2).
Gait and function in ambulant children
(GMFCS levels I–III)
The original and most common indication for the use of
BoNT-A in children with CP is in the management of
gait dysfunction, such as equinus gait or toe-walking.
More recently, the management of gait dysfunction has
been expanded by the injection of multiple muscles in
the lower limbs; in order of frequency: the gastrocso-
leus, hamstrings, hip adductors, tibialis posterior and
iliopsoas.
In the clinical setting, the description of gait and
function are highly relevant to not only the selection of
the individual child who may beneﬁt from BoNT-A
therapy, but also for the identiﬁcation of target muscles
and prescription of concurrent therapies, including se-
rial casting and choice of ankle-foot orthoses.
The gold standard for comprehensive assessment
of gait function in ambulant children with CP is
three-dimensional instrumented gait analysis (3DGA),
including various combinations of temporo-spatial
measurements, three-dimensional kinematics, kinetics,
dynamic electromyography and physiological testing
(Table 2). 3DGA is the cornerstone of outcome mea-
surement in clinical research trials of BoNT-A therapy
in ambulant children with CP, but it is limited in the
clinical context by cost and availability. In addition,
instrumented gait analysis is not feasible with many of
the children who are identiﬁed in the literature as being
the most responsive to BoNT-A therapy for gait dys-
function. This includes children aged one to four years,
with limited walking abilities and with limitations in
cooperation and physical size to complete an instru-
mented gait study. However, 3DGA has led to the
identiﬁcation of gait patterns, classiﬁcations and de-
scriptors, which are useful in the clinical setting includ-
ing the sagittal gait patterns identiﬁed by Rodda [37].
In the absence of 3DGA, clinicians in the multidis-
ciplinary team should employ observational gait
analysis when they assess childrens walking. These
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observations can be formalized by employing an
observational gait scale as such as the Physician Rating
Scale (PRS) (Table 2) [38].
The PRS is a qualitative, ordinal, observational scale
with good repeatability [39] and excellent intra-rater
reliability but limited inter-rater reliability, when used
for evaluating gait in children with CP [40].
Video gait analysis (VGA) has been widely used in
research studies investigating the use of BoNT-A for
gait dysfunction in children with CP and is increasingly
used in routine clinical management. The value of the
VGA is greatly enhanced when combined with the PRS
or one of several other observational gait scales.
Assessment of gross motor function, activities and
activity limitation
Functional goal attainment
It is important to note that the measurement of gross
motor function, activities and activity limitation in
children with CP is time-consuming, requires expertise
and is therefore expensive. This applies to themajority of
measures with established reliability, validity and sensi-
tivity, and as a result, they have limited use in routine
clinical practice, although essential in research studies.
The tension between measures with clinical relevance
and practicality and those which are relevant only to
research studies is not yet resolved in the literature. The
literature is clear, however, that the gold standard
measure of gross motor function in children with CP is
the GrossMotor FunctionMeasure (GMFM-66) [41,42]
(Table 2). The GMFM-66 quantiﬁes how much motor
function the child is able to demonstrate. It is a criterion-
referenced, observational measure for assessing change
over time in gross motor function and was designed
speciﬁcally for use in children with CP [41].
The Functional Independence Measure for Children
(WeeFIM) [43] (Table 2) and the Pediatric Evaluation
of Disability Inventory (PEDI) [44] (Table 2) are also
well established and useful in the research context for
children with more severe involvement (GMFCS levels
IV and V). The PEDI assesses a childs functional skills
and behaviours including caregiver assistance in com-
plex activities and can be useful for the child with more
signiﬁcant activity limitation (Table 2). The WeeFIM
assesses the impact of a disorder and the assistance
required rather than the functional ability, and whilst it
has a scoring system, which, in some instances, is not
sensitive enough for short-term pre- and post-treatment
comparisons, it has clinical utility for monitoring over
time, particularly in GMFCS V.
The Goal Attainment Scaling (GAS) [45] (Table 2)
helps to identify what types of changes are needed in
order for any clinical change to be meaningful to the
child and family. It also provides the family with a way
to evaluate progress, make informed decisions about
care and, where relevant, remain motivated to engage in
rehabilitation programmes.
Recommendation 2
• Muscle length (R2), Modiﬁed Tardieu Score (R1) and Australian
Spasticity Assessment Scale (ASAS) when presented together proﬁle
and quantify spasticity*
• Instrumented gait analysis is the most objective measure of gait and
function in children with CP but its use is largely limited to the
research context*
• VGA may be used both in research and clinical management*
• Observational gait analysis and the use of gait classiﬁcations and
observational gait scales are recommended for routine clinical use*
• A valid measure of gross motor functional ability that is appropriate
to the goal of treatment should be selected*
*Expert opinion.
Is there a role for Botulinum Neurotoxin type-
A in the multidisciplinary management of
children with cerebral palsy?
Animal studies relevant to the use of botulinum
neurotoxin type-A in children
Research into consequences of spasticity in children
with CP is hampered by the lack of a suitable animal
model. A number of researchers have attempted to
develop animal models of spasticity with little success.
When a standardized brain injury is inﬂicted on the
experimental animal, death or full recovery usually
results. It is exceedingly diﬃcult to produce a chronic
neurological lesion with the phenotypical manifestations
of CP. However, the hereditary spastic mouse is an
animal model that displays some features that are sim-
ilar to the problems of deﬁcient muscle tendon growth,
in relation to longitudinal bone growth, which occur in
the limbs of children with CP [46]. The spastic equinus
leading to toe-walking and deﬁcient gastrocsoleus
growth was described by Ziv and Rang in 1984 [46].
Cosgrove and Graham [47] provided proof of con-
cept that development of contracture in the mouse was
prevented by BoNT-A and paved the way for clinical
trials in the use of BoNT-A in children with CP.
However, in more recent studies, injections of BoNT-A
in juvenile rats without spastic muscle alteration pre-
vented maturational growth and induced progressive
and persistent atrophy of muscle [48]. Chen et al. [49]
found that injection of BoNT-A to the gastrocnemius
reduced the wet mass by 50%, and this atrophy was not
reversed by exercise.
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In another study, the same group found that BoNT-
A led to a reduction in gastrocnemius mass in juvenile
animals, leading to an alteration in myosin heavy chain
isoforms and reduction in titin content [50]. This may
have adverse implications for muscle strength.
In summary, injection of BoNT-A into juvenile mice
with hypertonia resulted in improved longitudinal
growth of the gastrocsoleus, whereas injection of
BoNT-A in a variety of experimental animals with
normal muscles led to reduction in cross-sectional area
and other changes that may have implications in respect
of producing weakness in the long term. It remains to
be seen which of these viewpoints and experimental
animals most closely replicates muscle growth in chil-
dren with CP.
By their nature, most randomized clinical human
trials have ethical, clinical and practical limitations
including relatively short duration of the period of
control. Parents may agree to have their children ran-
domized to either standard treatment or placebo
injection for relatively short periods of time, greatly
limiting the information that can be gleaned from RCTs
evaluating BoNT-A therapy. However, additional
information exists from cohort studies both prospective
and retrospective as to the overall contribution of
BoNT-A in the multidisciplinary management of chil-
dren with CP. In a long-term cohort study, Molenaers
et al. found that the introduction of BoNT-A and
clinical gait analysis resulted in a signiﬁcant number of
improvements in the management of children with CP
over a number of years [51]. These included the fact that
children were older at age of ﬁrst orthopaedic surgery,
fewer repeat surgeries were required and functional
outcomes were improved. Graham et al., in unpub-
lished observations, have found that the introduction of
BoNT-A over a 15- year period at The Royal Chil-
drens Hospital in Melbourne resulted in the elimina-
tion of isolated gastrocsoleus lengthening surgery with a
consequent dramatic reduction in the incidence of
crouch gait at 5–10 year follow-up. In simple terms, the
introduction of BoNT-A removed the pressure for
surgeons to perform lengthening of the gastrocsoleus in
younger children. Following one to ﬁve years of BoNT-A
management, children proceeded to single-event multi-
level surgery, which was preceded by instrumented gait
analysis. At that time, severe crouch gait, which his-
torically had been prevalent in the patient population,
had been almost eliminated.
Far from repeated injections of BoNT-A causing
weakness and increased gait dysfunction, the ability to
provide targeted management of spastic equinus has
resulted in greatly improved clinical outcomes [1,39,51,
Vuillermin C: Unpublished observations]. However,
concerns are sometimes expressed about the muscle
weakening eﬀects of BoNT-A in children with CP. In
the RCTs quoted in this consensus and in other non-
randomized trials, gait parameters have usually been
reported as improved. In one study, investigating
changes in sagittal ankle kinetics, Boyd et al. reported
relative normalization of ankle moments and increased
ankle power generation following BoNT-A injection
in children with CP. Whatever lessons are gleaned
from animal studies or from injection of adult volun-
teers with normal muscles, the kinetic evidence from
injection of BoNT-A in children with CP supports
improvements in kinetic parameters of gait.
What is the optimal botulinum toxin
treatment regimen?
A review of the RCTs of BoNT-A used in children with
CP revealed 29 heterogeneous studies including dose-
ranging studies in the management of spastic equinus
and prevention of hip displacement and multilevel
injections of lower limb muscles to improve gait and
functioning (Appendix 1). In the interests of further
analysis, the authors decided to group these heteroge-
neous studies into ﬁve principal groups, recognizing
that some studies could have been included in more
than one group.
Group 1 RCTs: dose-ranging and injection site
technique studies. N = 7
Recommended doses of BoNT-A have been established
by clinician-led dose-ranging studies combined with
expert opinion derived from other classes of studies. It
is important to note that dose-ranging studies have
largely focused on injection of the gastrocsoleus for
spastic equinus and that much less robust information
is available to guide dose selection in other muscle
groups and in multilevel injection protocols.
The authors found one Class I RCT [52] (Appen-
dix 1) that reported a dose-dependent relationship and
eﬃcacy for Dysport, supported by evidence from
RCTs graded as Class III [53–58]. It is notable that
there is no Class I RCT investigating the optimum dose
of BOTOX for spastic equinus in children with CP.
Inadequate information in respect of concealed alloca-
tion and the lack of a power analysis aﬀected the
quality of most trials. One Class I study investigated
three diﬀerent doses of Dysport to the gastrocsoleus in
comparison to placebo and clearly identiﬁed an opti-
mum dose, 20 Units/Kg [52]. Polak [54] compared two
doses of Dysport (8 Units/Kg versus 24 Units/Kg)
and found that the higher dose was more eﬀective
without any increase in adverse events. Wissel, investi-
gating two diﬀerent doses of BOTOX, found similar
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results in reduction in spasticity and improved range of
motion and gait parameters in the high-dose group, but
with a slightly increased incidence of minor adverse
events [53].
In a large study investigating three diﬀerent doses of
BOTOX [57], dose-dependent improvements in
dynamic deformities and gait patterns favoured the
higher doses without signiﬁcant diﬀerences in adverse
events; however, this study had methodological
weaknesses.
A small study utilizing single-site injection of the
gastrocsoleus was compared with multiple-site injec-
tions, and no signiﬁcant diﬀerences were found in
outcomes [55].
Group 2 RCTs: BoNT-A versus placebo/control in
spastic equinus. N = 7
The seven studies in this group were graded by the
authors as two Class I and ﬁve Class II using the AAN
criteria (Appendix 1). All seven studies are supportive
of BoNT-A injection in the management of spastic
equinus and constitute level I evidence and Grade A
treatment recommendation for this indication. The
outcome measures reported in these studies vary in
complexity, reliability and ICF domain with earlier
studies utilizing the PRS and 3DGA, and more recent
studies including measures of gross motor function
(GMFM) as well as adding psychometric reﬁnements of
the PRS to describe outcomes [59]. Class I evidence now
exists to conﬁrm signiﬁcant beneﬁts in terms of objec-
tive gait parameters when BOTOX is used to manage
spastic equinus [60]. Whilst the treatment size eﬀect in
terms of gait improvement is substantial, improvements
in the GMFM are notably smaller and less consistent
[61–63]. The Class I evidence rating refers to improve-
ments in gait leading to a level A recommendation.
However, improvements in gross motor function were
found only in Class II studies, leading to a level B
grading (that is to say, probably eﬀective).
Group 3 RCTs: BoNT-A injection compared to serial
casting for spastic equinus. N = 5
BoNT-A has historically been the most frequently used
alternative to serial casting. Therefore, many studies
have compared the outcomes of injection of BoNT-A
with serial casting for the management of spastic
equinus (Appendix 1) [39,64–67]. Collectively, these
studies show inconclusive and conﬂicting diﬀerences
between serial casting and BoNT-A. However, these
studies were small, underpowered and some lacked
objective outcome measures, with frequent failure to
diﬀerentiate the goal of equinus contracture manage-
ment from the goal of dynamic equinus management,
thus making deﬁnitive conclusions diﬃcult. Findings
include (i) improvements in sagittal ankle kinematics at
two weeks post serial casting and two weeks post
injection of BoNT-A with the serial casting group
relapsing to baseline levels at 12 weeks post-interven-
tion, whereas the improvements in the BoNT-A group
were sustained [39]; (ii) signiﬁcant incidence of adverse
eﬀects from serial casting on gait resulting in a signiﬁ-
cant parental preference for injections [64]; (iii) reduc-
tion in spasticity, some improvements in gait and a
small increase in GMFM walking scale favouring
injection of BoNT-A combined with serial casting
compared with BoNT-A alone [65]; (iv) no added
improvements in outcomes from injection of BoNT-A
combined with serial casting compared with serial
casting alone [66]; and (v) no signiﬁcant improvements
in BoNT-A only group, but signiﬁcant improvements in
gait parameters and other outcome measures in the two
groups that received serial casting ± BoNT-A [67]. The
eﬀects of serial casting seem to be at least as strong, and
in some studies stronger, than the eﬀects of injection of
BoNT-A, but this must be balanced by the preferences
of parents.
There appeared to be a trend supporting the eﬀects of
serial casting combined with injection of BoNT-A as
shown by muscle length, spasticity measures and gait
parameters, but with limited beneﬁts on functional
ability.
Group 4 RCTs: injection of the adductor and
hamstring muscles. N = 4
Injection of the adductor and hamstring muscle groups
in children with CP (GMFCS I-III) may be as part of
multilevel injection protocols aiming to improve gait
and functioning. They are also used in more severely
involved children (GMFCS IV & V) in an attempt to
improve other aspects of function and positioning or in
the prevention of progressive hip displacement [68–71].
One Class I study investigating the outcome of adduc-
tor and hamstring injection to improve function in
children with CP (Appendix 1) reported a signiﬁcant
reduction in adductor spasticity, no change in GMFM
and a signiﬁcant improvement in GAS for the inter-
vention group [69]. Similarly, the Class III study [68]
also reported no signiﬁcant diﬀerence in GMFM be-
tween the treatment and control groups. In contrast,
Hazneci [70] (Class III) compared BoNT-A injected
into the adductor and hamstring muscles to a John-
stone pressure splint (JPS) and reported GMFM out-
comes were better in the injection group.
Graham [71] (Class I) reported the outcome of a
multicentre study using serial injections to the hip
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adductors and hamstrings combined with use of the
standing, walking and sitting hip (SWASH) brace
compared with standard management (Appendix 1).
Whilst children in the treatment group progressed to
surgery at a signiﬁcantly lower rate than those in the
control group (possibly inﬂuenced by the rate of
progression of contractures), the authors concluded
this was not an eﬀective way to manage hip displace-
ment in the long term. Moreover, a signiﬁcant number
of adverse events were reported in the BoNT-A group,
and, in a previous subgroup analysis, no signiﬁcant
improvement in GMFM was found.
In summary, taking into consideration the class of
the study and the direction of the change in outcome
measure, there is a Grade A recommendation that
BoNT-A injections to the adductors and hamstrings is
not effective to improve gross motor function in chil-
dren with CP, as determined by GMFM. There is a
Grade A recommendation that BoNT-A injections are
effective in delaying the need for surgery in the man-
agement of hip displacement in children with CP, but
only in the short term. There is a level C recommen-
dation that BoNT-A injections are possibly eﬀective in
children achieving intervention goals as determined by
the GAS.
Group 5 RCTs: multilevel BoNT-A injections to
improve gait and functioning. N = 6
The RCTs in this group were even more heterogeneous
in terms of study populations, quality of RCT, injection
protocols and outcome measures than the previously
reported groups [72–77].
Of the six RCTs identiﬁed, the authors graded four
as Class II and two as Class III, with no studies
reaching a Class I grading (Appendix 1). The studies
reported widely diﬀerent outcome measures, with the
study by Scholtes et al., although included twice,
presumably reports the same patient cohort. The 2006
study by Scholtes [74] reports gross motor outcomes,
and the 2007 study [75] reports spasticity, muscle
length and gait outcomes. In this group, only one
study reports the following outcomes: Vulpe Assess-
ment Battery (VAB) [72], GAS [4], 3DGA [75] and
PEDI [77]. In contrast, four studies reported outcomes
in terms of gross motor function, principally using the
GMFM [72,74,76,77]. However, the changes in gross
motor function were contradictory, with two studies
[72,77] ﬁnding no signiﬁcant improvement in gross
motor function and two studies [74,76] reporting a
small improvement. Therefore, the classiﬁcation of
recommendation for multilevel injections is graded as
level U. That is to say, current data are inadequate or
conﬂicting.
Comparisons of the studies reporting variable chan-
ges in gross motor function in children with CP show
considerable variation in age and GMFCS levels.
Studies reporting younger children at GMFCS levels I
and II have found more consistent improvements in
gross motor function. In those studies investigating
changes in gross motor function in older children and at
GMFCS levels III and IV, either less improvement or
no improvement in gross motor function is generally
reported. In older children with more physical limita-
tions, there may be less potential to show improvement
in gross motor function, and the presence of occult
contractures may also be an important factor in
decreasing the beneﬁts of BoNT-A injection.
Recommendation 3
• BoNT-A is established as effective in the management of spastic
equinus to improve gait. (level A)
• BoNT-A is probably effective to improve goal attainment and
function in the management of spastic equinus (level B)
• BoNT-A is similar to serial casting in the management of spastic
equinus with current data being inadequate or conﬂicting (level U)
• BoNT-A injections to the adductor muscles is probably effective in
some speciﬁc areas of goal attainment (level B)
• BoNT-A injections to the adductor muscles do not improve gross
motor function (level A)
• BoNT-Ainjections to theadductor (andhamstring)musclesmaydelay
hip displacement, but does not affect long-term outcome (level A)
• BoNT-A injections to multiple lower limb muscles have inadequate
and conﬂicting data in respect of gait, goal attainment and function
(level U)
Injection protocols, dose, dilution and
injection sites
Given the widespread use of BoNT-A therapy in chil-
dren with CP, the multiple indications and heteroge-
neous groupings of target muscles, it is unsurprising
that the evidence base for promoting safety and eﬃcacy
remains very limited, and much of the current clinical
use of BoNT-A in children with CP remains oﬀ label.
Two commercially available BoNT-A preparations
are regularly used in children with CP: BOTOX
(Allergan Pty Ltd) and Dysport (Ipsen). There is very
little published information on the use the Xeomin
(Merz Pharmaceuticals) BoNT-A product, which was
launched in 2005. Each preparation has a unique bio-
logical potency, and there are no ﬁrmly established
conversion factors. It is important for clinicians to be
aware that the doses for these products are not inter-
changeable. We strongly advise against the use of
conversion factors between diﬀerent preparations on
BoNT-A.
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There are no dose-ranging studies that address the
optimum dose of BOTOX. Recommendations in
previous studies, consensus statements and this docu-
ment are expert opinion; that is to say, no RCTs have
been published. Given recent concerns about adverse
events, the authors have chosen total doses in units per
Kg body weight for BOTOX, which are intermediate
between the ﬁgures proposed in two previous consensus
statements, and which err on the side of caution
(Table 3). It is the responsibility of the treating physi-
cian to carefully choose the dose they consider appro-
priate for the individual case concerned.
In addition to the RCTs reviewed in detail by the
authors, review of non-RCT literature conﬁrms marked
escalation in recommended doses of BOTOX, both in
relation to speciﬁc indications such as spastic equinus as
well as in multilevel protocols. For example, in 2000,
Graham [78] made the following recommendations:
maximum dose at any one site 50 Units, maximum dose
in any one injection session 300 Units or 12 Units per
Kg. In 2006, Heinen [79] in a European consensus
statement reported a published total dose range up to
20–24 Units per Kg for this preparation (Table 3). It
should be noted that both of these suggested upper dose
limits were determined by expert opinion, not sup-
ported by clinical trial.
One Class I study exists for the use of Dysport, and
this is only for the indication of spastic equinus [52].
(Table 3).
Although the incidence of adverse events following
injection of BoNT-A in the RCTs reviewed in this
paper and in other literature remains relatively low,
systemic adverse events can include generalized weak-
ness, diplopia, dysphagia, aspiration, pneumonia and
death. This serves as a warning that systemic spread of
BoNT-A may occur in children with CP and much
further work is required before high-dose protocols can
be accepted as safe. Given that the major risks of
serious systemic adverse events reside in the child, it
seems prudent to make recommendations based on
Table 3 Products and doses
Product
Dose U/kg body weight
Maximum Total DoseRange in literature Recommendation
BOTOX 6–24 U/Kg
(up to 30 U/Kg used
in occasional multilevel
injections)
GMFCS I–IV without risk factors: 16–20 U/Kg
GMFCS V with risk factors: 12–16 U/Kg*
<300 U [53,57]
<400–600 U [79]
Dysport 10–30 U/Kg 20 U/Kg [52]
(level B recommendation)
200–500 U [54] (level U
Recommendation)
<900 U [79]
Risk factors include symptoms and signs of pseudobulbar palsy, swallowing difﬁculties, history of aspiration and respiratory disease. When risk
factors are present, evaluate the level of risk and either further reduce the total dose or avoid using BoNT-A.
*Expert opinion.
Table 4 Favourable Response to BoNT-A and physiotherapy
Aim Expected Outcome Indication
Grade of
Recommendation
Reduction in body
structures impairment
Reduction in spasticity
and improved dynamic
ROM
Decreased involuntary over-activity of injected muscles. Observed
by a reduction in R1 R2 difference, measured on the ASAS [36]
and MTS [18].
A
Improved selective motor
control
Improved ability to isolate and selectively control ankle
movements. Selective motor control is measured via Selective
Motor Control Scale [18].
U
Improved strength Greater strength in agonist and antagonist muscle groups,
measured via a dynamometer or the Medical Research Council
scale (graded 1–5).
U
Improved passive ROM BoNT-A in combination with casting is used to reduce contracture.
Improved passive ROM is measured via goniometry.
B
Improved functional
activity performance
Improved function and
task performance
Improvements in individualized goal performance of functional
tasks (e.g. walking, running, kicking a ball). Observed by an
increase in GMFM scores [99] and /or measured by an increase in
GAS [45].
B
Improved quality of life
and personal factors
Reduction in pain Decreased pain and spasm, measured on a Visual Analogue Scale
(VAS), COPM [100], GAS [45] WeeFIM [43] or PEDI [44].
U
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GMFCS level and pre-existing medical co-morbidities.
Additionally, dose calculation will be inﬂuenced by
muscle size, muscle activity and experience from pre-
vious treatments with BoNT. Risk factors include
symptoms and signs of pseudobulbar palsy, swallowing
diﬃculties, history of aspiration and respiratory dis-
ease. When risk factors are present, evaluate the level of
risk and either further reduce the total dose or avoid
using BoNT-A.
Choice of the number and position of injection sites
has been based on anatomical considerations more re-
cently supported by anatomical studies investigating the
location of neuromuscular junctions and motor end
plates. However, there are no high-level clinical trials
supporting injection site choice.
Traditionally, the localization of target muscle has
been by using a combination of anatomical landmarks
and palpation. Early protocols also suggested the use of
moving distal joints through a range of motion to ob-
serve the motion of a needle placed in the target muscle.
More recently, studies have conﬁrmed that target
muscle identiﬁcation by palpation and anatomical
landmarks alone is inaccurate, except for the gastro-
csoleus [80].
Both electrical stimulation and real-time ultrasound
improve the accuracy of injection; however, electrical
stimulation is uncomfortable and usually requires mask
anaesthesia. Ultrasound is emerging as the preferred
modality to improve the accuracy of intramuscular
injection of BoNT-A in children with CP. It is quick to
perform and pain-free, and real-time visualization of the
spread of BoNT-A within the targeted muscle can be
used to document accurate intervention. Additional
information concerningmuscle size (atrophy) and degree
of ﬁbrosis can also be visualized using ultrasound and
has the potential to add additional information for dose
calculations prior to injection of the targeted muscle
[81,82].
Although recent work using electrical stimulation
and ultrasound in children with CP has demonstrated
improved accuracy of delivery of BoNT-A to the target
muscle, the clinical relevance of improved injection
accuracy remains a matter for further study.
In the RCTs reported in this review, dilution of
BoNT-A varies, and there is no high-level evidence to
guide choice of dilution. In children with CP, the
recommended dilution for the BOTOX product
varies from 100 Units reconstituted in between 1 to 4
mLs of normal saline. Evidence from the adult liter-
ature suggests that higher dilutions may be more
eﬀective for a given dose of toxin. It is not known in
children with CP whether dose dilution has an impact
on the rate of local spread and/or systemic adverse
events.
Recommendations for delivery of BoNT-A
The onset of the therapeutic eﬀect of BoNT-A occurs
within the ﬁrst few days, peaking approximately four
weeks after injection. Duration of eﬀect is approxi-
mately three to six months. The main clinical indicator
for re-injection is the return of muscle spasticity. Other
factors involved in decision-making about re-injection
include prior clinical response/s (balancing the positive
eﬀects and adverse events) and length of time elapsed
since last injection (frequent, repeat injections elevate
the risk of developing an antibody response, which can
result in non-response to treatment).
Conservative re-injection intervals of six months or
more are recommended in children with CP. Where the
treatment is acute and for short duration, such as
traumatic brain injury, re-injection intervals may be as
short as three months.
Recommendation 4
• Conversion factors between different preparations of BoNT-A can
lead to life threatening miscalculations and their use is strongly
discouraged. Rates and sizes of reactions may be different between
preparations (level A).
• Determination of dose relates to severity of spasticity, goal of
treatment, size of targeted muscle, distribution of neuromuscular
junctions with that muscle and previous responses to BoNT-A (if
known).
• Dose should be cautiously selected in patients of GMFCS level V
and any patient with dysphagia or breathing problems.
• Injection interval for serial BoNT-A should generally be no less than
six months.
• Precise localization of muscle injection sites helps to improve the
safety proﬁle of BoNT-A by reducing the likelihood of unwanted
toxin migration (level U)*. Use injection techniques which allow the
operator to accurately isolate the target muscle (ultrasound is the
preferred method).
*Expert opinion
What are the optimal adjunctive
interventions?
During the past decade, there has been a switch in cli-
nicians thinking towards looking for adjunctive inter-
ventions to augment BoNT-A therapy. In fact, BoNT-A
is the adjunctive intervention.
The therapeutic interventions aimed at improving
function or reducing pain and care-giver burden have
long been in place, and it was in the early 1990s that
BoNT-A became available as an adjunctive clinical tool
that assisted in achievement of these goals by directly
reducing spasticity. The challenge of determining what
and how interventions are best combined with lower
limb BoNT-A to achieve optimal outcomes has been
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recognized since the early use of BoNT-A in children
with CP [60,68,71,83]. Despite this, there is a paucity of
high-level evidence for speciﬁc adjunctive interventions
[84–86]. The current practice of combining therapies
with BoNT-A is based largely on the clinical reasoning
that a window of opportunity exists with BoNT-A that
allows elongation of shortened muscles and improved
motor control; that this period may be long enough for
muscle growth, skill development and improvement in
function or ease of care and that these gains are facili-
tated by adjunctive interventions.
The most commonly cited adjunctive interventions to
lower limb BoNT-A are casting, orthotic management
(ankle-foot orthoses) and physiotherapy (strengthening,
stretching, targeted motor training). These interven-
tions are generally considered essential components of
post-BoNT-A care [18,74,75,87,88].
Appendix 2 provides a summary of high-level
evidence for adjunctive interventions. Other physio-
therapy approaches such as neurodevelopmental
therapy (NDT) have been cited as an adjunct to BoNT-A
[70,72,89] and appear to be more commonly used for
non-ambulant children. Night-splinting [87] and use of
adaptive devices or equipment for positioning [84,89]
are considered by some authors as part of optimal or-
thotic management. Electrical stimulation and other
electrotherapy modalities [56,89], along with a range of
medically and surgically based interventions including
oral medications, phenol injections, orthopaedic and
neurosurgical interventions, have also been discussed in
the literature; however, there are insuﬃcient data in any
of these areas to make recommendations.
Casting as an adjunctive intervention for management
of spastic equinus:
Two Class II studies have compared the eﬀect of casting
plus BoNT-A with BoNT-A alone [65,67] or with
casting alone [66,67]. Bottos [65] showed improvements
in GMFM walking domain, Ashworth Scale (AS) and
stride length for the BoNT-A plus casting group. Sim-
ilarly, Ackman [67] reported signiﬁcant improvements
in ankle kinematics, spasticity, passive ROM and
dorsiﬂexion strength in both the casting and the BoNT-
A plus casting group, but no signiﬁcant diﬀerences in
the BoNT-A alone group. In contrast, Kay [66]
reported no beneﬁcial eﬀect of BoNT-A plus casting
over casting alone, noting a more rapid return of
spasticity following BoNT-A plus casting. A compari-
son of casting-prior-to-BoNT-A with casting-following-
BoNT-A [88] showed only minimal reduction in length
of time of casting when applied following BoNT-A.
The existing studies provide neither strong nor con-
sistent evidence that casting provides additional beneﬁt
to BoNT-A (level U recommendation) or that the order
of casting (either prior to or following BoNT-A) aﬀects
outcome (level U recommendation).
Orthoses (AFOs) as an adjunctive intervention for
BoNT-A in the management of spastic equinus:
The systematic review of Figueiredo [89] identiﬁed 20
studies addressing eﬃcacy of ankle-foot orthoses (AFOs)
in children with CP (in isolation from lower limb BoNT-
A). All 20 studies were classed at low levels of evidence.
Whilst many of the studies combined AFOs with lower
limb BoNT-A and provided some information on eﬃ-
cacy of combined interventions, they did not provide
evidence of AFOs as an adjunctive intervention. Only
one small RCT [65] compared BoNT-A plus AFO plus
physiotherapy (PT) with BoNT-A plus casting plus PT
and reported the group receiving casting made greater
improvements at four months post-BoNT-A as mea-
sured by AS, GMFM and gait analysis.
Physiotherapy as an adjunctive intervention
An ongoing challenge when reviewing the evidence is
determining what is encompassed by the term physio-
therapy. There is often limited detail regarding pro-
gramme content, the modalities used, dose and delivery
model. This is the case for the studies included in this
review. Physiotherapy programmes vary from detailed
programmes including strengthening, stretching and
targeted motor training delivered three times a week for
12 weeks, which may be combined with casting and
orthotic or night splint use [74–76] or neurodevelop-
mental therapy (NDT) three times weekly for three
months [70] to regular or usual physiotherapy. Lower
limb BoNT-A and physiotherapy have been combined
in the majority (24 of 29) of the RCTs in Appendix 1,
which represents the highest quality of evidence avail-
able for lower limb BoNT-A (three Class I, 13 Class II
and eight Class III studies). Despite the high proportion
of RCTs combining physiotherapy plus BoNT-A in the
experimental group of each trial, there is insuﬃcient
evidence to support or refute physiotherapy interven-
tions as an adjunct to lower limb BoNT-A (level U
recommendation) as no high-level studies have investi-
gated these interventions speciﬁcally as adjunctive
interventions. A number of speciﬁc physiotherapy
interventions that are commonly used in clinical prac-
tice have been validated in isolation from BoNT-A. For
example, there is high-level evidence that strengthening
in children with CP is eﬀective in isolation (level B
recommendation). Other physiotherapy interventions
have conﬂicting or limited evidence to support them,
however, are established current practice in many
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centres. Expert opinion supports combining physio-
therapy and BoNT-A (Table 4).
Recommendation 5
• Serial casting should follow BoNT-A for management of ﬁxed calf
contracture (level U).*
• AFOs are an effective adjunctive intervention to improve gait and
protect foot integrity (level U).*
• Prolonged stretching is an adjunctive intervention to BoNT-A to
assist in management of muscle length (level U).*
• Strengthening is an essential adjunctive intervention to BoNT-A
when goals to improve motor function are identiﬁed (level U).*
• Targeted motor training is as an essential adjunctive intervention
when goals to improve motor function are identiﬁed (level U).*
*Expert opinion
Management algorithm
How should patients be monitored?
BoNT-A is safe and eﬀective [90]. The focal, temporary
and reversible nature of the drug contributes to its
safety [90]. However, prior to commencement of BoNT-
A intervention, children and parents should be
informed about the potential risks, side eﬀects and
adverse events of the treatment, including, but not
limited to, procedural risks. Appropriate consent
should be obtained. BoNT-A is usually well tolerated
by children with lower limb spasticity caused by CP;
however, side eﬀects and adverse events can occur (rates
of adverse events in clinical trials are: 25% for those
treated with BoNT-A and 15% for untreated controls)
[90]. Children injected with higher total doses experi-
ence more adverse events [91].
Eﬀorts should be made to appropriately monitor
and reduce or prevent side eﬀects and adverse events.
The goal of review is to monitor not only the imme-
diate eﬀects of the BoNT-A injection, but to inform
ongoing management decisions including, but not
limited to, future injections. Post-injection review
should occur within six weeks of BoNT-A injection.
Where resources do not allow clinical review for all
treated children, those who are receiving the treatment
for the ﬁrst time and those considered to be at higher
risk of experiencing an adverse event or side aﬀect
Re-assessment
Physiotherapy after BoNT-A injection
9. Select muscles for injection
10. Select dose and dilution
11. Localise muscles for injection
12. Plan/coordinate therapy interventions
13. Is spasticity reduced?
Determine injection plan
A
Yes No
Yes No
18. Is pain reduced/
easier positioning?
Improve
function/gait
Manage symptoms
e.g pain, positioning
Progressive 
resistance 
strength
training
14. Specific targeted motor training
15. Is strength decreased?
16. Is contracture present?
Yes No
Consider
equipment 
review &/or
further pain 
assessment
Yes No
Yes NoCast to gain ROM
17. Is foot prepositioned for gait?
19. Is QOL/family satisfaction improved?
20. Is there a risk of loss of muscle length?
Yes No
Consider
AFO No
Consider AFO/
maintenance 
home program
Yes
B
21. Have goals been achieved?
22. Is response favourable?
B
Assess whyYes No
Discontinue
Consider
surgical
consultation
Consider
re-injection
Consider: tolerance of
procedure, adverse
events, re-injection 
time-line, dosage used,
muscles selected,
post treatment provided, 
BoNT-A brand used 
Yes No
Assessment
Child presents for LL BoNT-A assessment
Assess strength,
selective motor control
Consider generalised 
spasticity/dystonia
medication
Discontinue assessment 
for BoNT-A
A
3. Set family goals (GAS, based on GMFM
or gait deviation)
1. Is increased muscle tone present?
4. Is spasticity limiting goal achievement?
6. Is there full passive muscle 
length (goniometry)?
7. Determine purpose of BoNT-A
Improve
function/gait
Manage symptoms
e.g pain, positioning
2. Establish presence & severity of
spasticity (velocity dependent hypertonia)
(MTS, ROM, ASAS)
5. Is spasticity focal/is 
focal spasticity within generalised 
spasticity a limiting factor?
Yes No
1. Cast to gain ROM if 
 contracture not longstanding.
2. Consider BoNT-A pre-casting
3. Consider surgery if
 contracture is severe 
 &/or longstanding
Yes No
Yes No
Yes No
8. Determine gross 
motor function/quality 
of gait (GMFM, 
PRS, 3DGA)
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should be prioritized. Telephone review can some-
times replace clinical review for children receiving
unchanging serial BoNT-A treatment and who have
no previous history of an adverse event. Families must
be taught how to monitor adverse events to maximize
safety.
Adverse events arising from BoNT-A injections are
categorized as either local or generalized. Local
adverse events are common (range 0–30%) but are
usually mild and self-limiting. They include pain,
swelling and bruising [92]. The most commonly
reported events after lower limb BoNT-A include
excessive localized weakness in the lower limb result-
ing in falls and clumsiness (which is not unexpected
given the intended clinical action of BoNT-A is to
dampen hyperactivity of injected muscles). Children
who experience trauma from the injections or exces-
sive local weakening, aﬀecting their balance and
increasing the number of falls, are more likely to
discontinue BoNT-A intervention [93]. Local reactions
can also occur if the BoNT-A migrates into adjacent
muscles [90].
Generalized adverse events, or systemic reactions, are
very rare in this population [94–96]. Systemic adverse
reactions following BoNT-A injection include nausea,
fatigue, malaise bladder incontinence or disturbance,
ﬂu-like symptoms and rash [90]. Children with more
severe motor involvement (GMFCS IV–V) and pre-
existing laryngeal and pharyngeal dysfunction are
thought to be most at risk [96]. The time to onset of
systemic reactions can vary, from immediately post-
injection to weeks after injection. Respiratory compli-
cations may be related to both procedural factors as
well as the BoNT-A. For example, multilevel injection
protocols involving the use of electrical stimulation for
target muscle identiﬁcation frequently require the use of
anaesthesia. General anaesthesia in its own right is a
risk factor for aspiration and chest infection, and it can
be diﬃcult to separate the risk of the procedure from
the risk of injection. However, incontinence of bladder
and bowel is clearly a systemic response to BoNT-A
injection and has been reported in many studies at
varying BoNT-A doses. Incontinence is clearly a sys-
temic pharmacologic adverse event and is not related to
procedural issues.
In rare cases, hospitalization and death have been
reported [97]. There are two published reports of
fatalities, both thought to be not related to the injec-
tion. There are no reports of increased seizures relative
to controls.
Non-response can also occur with BoNT-A and is
thought to be caused by antibody formation [93,98].
The likelihood of non-response increases with repeated
injections [99].
Recommendation 6
• Lower doses coupled with careful monitoring, especially of oral
feeding, are recommended for patients with known risk factors (level
U)*.
• Verbal and written explanation of both potential beneﬁts and
possible adverse events should be given to parents or carers before
the ﬁrst injection. Parents should be taught how to identify the signs
and symptoms of an adverse event (such as dysphagia, dysphonia,
dyspnoea, respiratory distress, generalized weakness or inconti-
nence) and instructed to seek medical attention immediately if the
child experiences difﬁculty swallowing, talking, breathing, or muscle
weakness.
• Clinical review should occur 26 weeks following BoNT-A injection.
• Structured review of functional outcomes should occur four–six
months following BoNT-A injection.
What are the expected outcomes of botulinum
toxin and therapy?
A favourable response to BoNT-A is reduction in
spasticity (which is the primary aim of the treatment)
and improvement in the pre-set individualized goals.
Level A evidence supports the eﬀectiveness of BoNT-
A for reducing muscle spasticity in children with lower
limb spasticity. Secondary aims and potential favour-
able responses of BoNT-A combined with physiother-
apy are to create a window of opportunity for
increasing functional activity, reducing caregiver bur-
den and improving symptom management. Whilst the
presented RCTs have shown the functional and gait
outcomes of BoNT-A, more rigorous research is needed
into desired outcomes relating to caregiver burden and
symptom management such as pain control.
Failure to respond to BoNT-A, or an unfavourable
response, is characterized by the following:
1 no or insuﬃcient reduction in muscle spasticity (dose,
needle placement and antibody response factors may
be responsible);
2 no translation to desired gains in function or symp-
tom management from the reduction in spasticity;
and
3 adverse events that outweigh the beneﬁts experienced.
Future directions
There are many unresolved issues. The literature does
not yet deﬁne the ideal time to start BoNT-A therapy,
the ideal frequency of injection, nor when to deﬁnitively
cease BoNT-A therapy. There is a need for longer term
studies, which include multiple treatment cycles. Clearer
knowledge of the incidence of background morbidity in
the CP population is needed to enable clinicians to dis-
tinguish what are true BoNT-A adverse eﬀects.
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There is a paucity of evidence related to the eﬀects of
BoNT-A on muscle strength and muscle morphology,
and further studies in this area should consider the out-
come measures of cross-sectional anatomy using ultra-
sound, MRI and, if possible, ﬁne-structural analysis.
Most of the literature reviewed in this paper focused
on measures of body function and structure (good
evidence of local technical response of BoNT-A), but
little in the domains of activity or participation, and this
needs to be addressed in future studies with objective,
gold standard outcome measures across all domains of
the ICF.
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